IP Library Granted Patent US 11,345,757
Granted Patent B2
US 11,345,757 · App. 16/635,526 · Granted May 31, 2022

Anti-CD39 antibodies

Inventors: Vanessa Soros (San Francisco, CA); Maria Kovalenko (Portola Valley, CA); John Corbin (Oakland, CA); Courtney Beers (San Francisco, CA); Paul Fredrick Widboom (Hanover, NH); Joseph Robert Warfield (White River Junction, VT)
Assignee: Trishula Therapeutics, Inc.
C07K16/2896A61K39/3955A61P37/04C12N15/11C12N15/63G01N33/566A61K39/39541A61K45/06A61K2039/505C07K2317/21C07K2317/24C07K2317/31C07K2317/33C07K2317/56C07K2317/565C07K2317/74C07K2317/76C07K2317/77C07K2317/92G01N2333/70596G01N2500/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,345,757
App. No.
16/635,526
Granted
May 31, 2022
Kind
B2
Abstract

Provided herein are antibodies that selectively bind to CD39 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.

Claims (14)

1. An isolated antibody molecule capable of binding to human CD39 (hCD39), comprising a heavy chain variable region (VH) and a light chain variable region (VL),

the VH comprising,

a) a VHCDR1 having a sequence set forth in SEQ ID NO: 2 or SEQ ID NO: 26,

b) a VHCDR2 having a sequence set forth in SEQ ID NO: 47 or SEQ ID NO: 64, and

c) a VHCDR3 having a sequence set forth in SEQ ID NO: 83; and the VL comprising,

a) a VLCDR1 having a sequence set forth in SEQ ID NO: 111,

b) a VLCDR2 having a sequence set forth in SEQ ID NO: 126, and

c) a VLCDR3 having a sequence set forth in SEQ ID NO: 142.

2. The isolated antibody molecule capable of binding to human CD39 (hCD39) comprising a heavy chain variable region (VH) and a light chain variable region (VL) according to claim 1 , wherein the VH comprises a VH having the sequence set forth in SEQ ID NO: 180 and the VL comprises a VL having the sequence set forth in SEQ ID NO: 220.

3. An isolated nucleic acid encoding the isolated antibody molecule according to claim 1 .

4. An expression vector comprising the nucleic acid according to claim 3 .

5. A prokaryotic or eukaryotic host cell comprising the vector of claim 4 .

6. A method for the production of an isolated antibody molecule comprising the steps of expressing a nucleic acid according to claim 3 in a prokaryotic or eukaryotic host cell and recovering the antibody molecule from the cell or the cell culture supernatant.

7. An isolated antibody molecule capable of binding to human CD39 (hCD39), comprising a heavy chain and a light chain, the heavy chain comprising a molecule having a sequence consisting of SEQ ID NO: 255 and the light chain comprising a molecule having a sequence consisting of SEQ ID NO: 256.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNORS NAME PREVIOUSLY RECORDED AT REEL: 053974 FRAME: 0562. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 12, 2021
From: TIZONA THERAPEUTICS
To: TRISHULA THERAPEUTICS, INC.
Reel/Frame 055288/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2020
From: TIZONA THERAPEUTICS, INC.
To: TRISHULA THERAPEUTICS, INC.
Reel/Frame 053974/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: WARFIELD, JOSEPH ROBERT; WIDBOOM, PAUL FREDRICK
To: ADIMAB, LLC
Reel/Frame 052089/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: ADIMAB, LLC
To: TIZONA THERAPEUTICS
Reel/Frame 052089/0604 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: SOROS, VANESSA; KOVALENKO, MARIA; CORBIN, JOHN; BEERS, COURTNEY
To: TIZONA THERAPEUTICS
Reel/Frame 052089/0708 →
Continuity (2)
Provisional Application 62539527 · Jul 31, 2017
Related Publication 20210009708A1 · Jan 14, 2021